JP7522661B2 - ビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 - Google Patents

ビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 Download PDF

Info

Publication number
JP7522661B2
JP7522661B2 JP2020563505A JP2020563505A JP7522661B2 JP 7522661 B2 JP7522661 B2 JP 7522661B2 JP 2020563505 A JP2020563505 A JP 2020563505A JP 2020563505 A JP2020563505 A JP 2020563505A JP 7522661 B2 JP7522661 B2 JP 7522661B2
Authority
JP
Japan
Prior art keywords
cancer
formula
another embodiment
compound
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020563505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523169A (ja
JP2021523169A5 (enExample
Inventor
デイビス、マッティ
Original Assignee
アヤラ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アヤラ ファーマシューティカルズ インコーポレイテッド filed Critical アヤラ ファーマシューティカルズ インコーポレイテッド
Publication of JP2021523169A publication Critical patent/JP2021523169A/ja
Publication of JP2021523169A5 publication Critical patent/JP2021523169A5/ja
Application granted granted Critical
Publication of JP7522661B2 publication Critical patent/JP7522661B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020563505A 2018-05-06 2019-05-05 ビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 Active JP7522661B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862667540P 2018-05-06 2018-05-06
US62/667,540 2018-05-06
PCT/US2019/030771 WO2019217250A1 (en) 2018-05-06 2019-05-05 Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2021523169A JP2021523169A (ja) 2021-09-02
JP2021523169A5 JP2021523169A5 (enExample) 2022-04-19
JP7522661B2 true JP7522661B2 (ja) 2024-07-25

Family

ID=68468208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020563505A Active JP7522661B2 (ja) 2018-05-06 2019-05-05 ビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法

Country Status (12)

Country Link
US (2) US20210244745A1 (enExample)
EP (1) EP3790552A4 (enExample)
JP (1) JP7522661B2 (enExample)
KR (1) KR20210005714A (enExample)
CN (1) CN112218639A (enExample)
AU (2) AU2019266150A1 (enExample)
BR (1) BR112020022654A2 (enExample)
CA (1) CA3099479A1 (enExample)
IL (1) IL278492B2 (enExample)
MX (1) MX2020011826A (enExample)
SG (1) SG11202011041YA (enExample)
WO (1) WO2019217250A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210379079A1 (en) * 2018-05-06 2021-12-09 Ayala Pharmaceuticals Inc. Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
US20220339162A1 (en) * 2018-05-06 2022-10-27 Ayala Pharmaceuticals Inc. Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating desmoid tumors
EP3793564A4 (en) 2018-05-15 2022-03-30 Ayala Pharmaceuticals Inc. COMPOSITIONS CONTAINING BISFLUOROALKYL-L,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF ADENOCARCINOMA
BR112020023975A2 (pt) * 2018-05-24 2021-02-23 Ayala Pharmaceuticals Inc. composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas
JP2022533100A (ja) * 2019-05-15 2022-07-21 アヤラ ファーマシューティカルズ インコーポレイテッド Ｎｏｔｃｈ活性化乳がんを治療するためのビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物
US20240299411A1 (en) * 2021-05-13 2024-09-12 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502933A (ja) 2013-12-05 2017-01-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 求電子性官能基を有するヘテロアリールピリドン及びアザ−ピリドン化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
TWI530489B (zh) * 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
US20140357605A1 (en) * 2012-03-22 2014-12-04 Bristol-Myers Squibb Company Bis(fluoroalkyl)-1,4-benzodiazepinone compounds
AR087107A1 (es) * 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
EP2861255B1 (en) 2012-06-19 2019-10-09 The Broad Institute, Inc. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
TWI614238B (zh) * 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
JP2015531792A (ja) * 2012-09-21 2015-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ １，４−ベンゾジアゼピノン化合物のプロドラッグ
CN105101968A (zh) * 2013-04-04 2015-11-25 百时美施贵宝公司 治疗增殖性疾病的组合疗法
EP3212233B1 (en) * 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN120661674A (zh) * 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
MX380779B (es) 2016-04-12 2025-03-12 Lilly Co Eli Terapia combinatoria con inhibidores notch y cdk4/6
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
IL268349B2 (en) * 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615055A1 (en) * 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US11970542B2 (en) * 2017-11-08 2024-04-30 Fred Hutchinson Cancer Center Bispecific antibodies specific for treating hematological malignancies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502933A (ja) 2013-12-05 2017-01-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 求電子性官能基を有するヘテロアリールピリドン及びアザ−ピリドン化合物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Gavai AV et al.，ACS medicinal chemistry letters，2015年，Vol. 6，No. 5，pp.523-527.
LI M et al.，Molecular cancer therapeutics，2010年，Vol. 9，No. 12，pp.3200-3209.
Manigat L et al.，Neuro-Oncology，2015年，Vol. 17，Issue suppl_5，pp.v73-v77.，DOI: 10.1093/neuonc/nov212.16
Morgan KM et al.，Molecular cancer therapeutics，2017年，Vol. 16，No. 12，pp.2759-2769.
Rao SS et al.，Cancer research，2009年，Vol. 69，No. 7，pp.3060-3068.
Tijeras-Raballand A et al.，Molecular Cancer Therapeutics，Vol. 17，No. 1_Supplement，2018年01月，Abstract:B144，DOI: 10.1158/1535-7163.TARG-17-B144

Also Published As

Publication number Publication date
JP2021523169A (ja) 2021-09-02
KR20210005714A (ko) 2021-01-14
AU2019266150A1 (en) 2021-01-07
US20210244745A1 (en) 2021-08-12
EP3790552A4 (en) 2022-06-15
SG11202011041YA (en) 2020-12-30
IL278492B2 (en) 2025-03-01
CN112218639A (zh) 2021-01-12
US20210040050A1 (en) 2021-02-11
WO2019217250A1 (en) 2019-11-14
US12281085B2 (en) 2025-04-22
EP3790552A1 (en) 2021-03-17
IL278492B1 (en) 2024-11-01
IL278492A (enExample) 2021-01-31
MX2020011826A (es) 2021-01-15
AU2025201674A1 (en) 2025-03-27
CA3099479A1 (en) 2019-11-14
BR112020022654A2 (pt) 2021-03-09

Similar Documents

Publication Publication Date Title
US12281085B2 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
JP6433085B2 (ja) がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
US20210220372A1 (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
US12233072B2 (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating Adenoid Cystic Carcinoma
US20210379079A1 (en) Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
JP2016515625A (ja) 増殖性疾患を治療するための併用療法
HK40059920B (en) 2-acetylnaphtho[2,3-b]furan-4,9-dione for use on treating cancer
HK40059920A (en) 2-acetylnaphtho[2,3-b]furan-4,9-dione for use on treating cancer
CN117279637A (zh) 用于治疗癌症的包含双氟烷基-1,4-苯并二氮杂卓酮化合物的组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240412

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240712

R150 Certificate of patent or registration of utility model

Ref document number: 7522661

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150